ProjectEMPA-KIDNEY® Kids – A randomised, double-blind, placebo-controlled trial with anopen-label extension to assess the…
Basic data
Acronym:
EMPA-KIDNEY® Kids
Title:
A randomised, double-blind, placebo-controlled trial with anopen-label extension to assess the pharmacokinetics, safety,and efficacy of empagliflozin tablets in paediatric patientswith chronic kidney disease
Duration:
01/12/2025 to 31/12/2029
Abstract / short description:
The aim of this trial: Provide assessments of PK, safety, and efficacy of empagliflozin in a
broad patient population with proteinuric CKD, aged 2 to 17 years, regardless of etiology.
broad patient population with proteinuric CKD, aged 2 to 17 years, regardless of etiology.
Keywords:
chronic kidney disease
SGLT2 inhibitor
proteinuria
Involved staff
Managers
Faculty of Medicine
University of Tübingen
University of Tübingen
Other staff
Faculty of Medicine
University of Tübingen
University of Tübingen
Faculty of Medicine
University of Tübingen
University of Tübingen
Faculty of Medicine
University of Tübingen
University of Tübingen
Local organizational units
Paediatrics Department I and Polyclinic
University Children’s Hospital - Department of Paediatrics
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Ingelheim am Rhein, Rheinland-Pfalz, Germany